Society Testimony

Funding Recommendations for NIH and NIDDK House Appropriations Committee, Subcommittee on Labor-Health and Human Services-Education-and Related Agencies by E. Dale Abel, MD, PhD on behalf of the Friends of the National Institute of Diabetes and Digestive and Kidney Diseases May 19, 2021

May 19, 2021

Chairwoman DeLauro, Ranking Member Cole, and Members of the Subcommittee:

"My name is Dale Abel. As an endocrinologist and biomedical researcher myself, I am proud to represent the 35 patient, physician, and research organizations that are members of the Friends of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). We want first to thank you for your ongoing bipartisan investment in the National Institutes of Health (NIH). We are here today to ask you to support our FY 2022 NIH funding recommendation of at least $46.111 billion, a $3.177 billion increase over the comparable FY 2021 funding level for the NIH, which would allow for the NIH’s base budget to keep pace with the biomedical research and development price index of 2.3 % and allow meaningful growth of 5%. We also request a proportionate increase for the NIDDK of at least $157 million for a total of $2.289 billion in FY 2022."

arrowRead the Full Testimony

Last Updated:

Policy Communications

Take Action

Make Your Voice Heard

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your US representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your US representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.